Qrons Inc. (QRON)
USD 0.18
(0.0%)
USD 0.18
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -643.67 Thousand USD | -2.23% |
| 2022 | -629.62 Thousand USD | 21.49% |
| 2021 | -801.95 Thousand USD | -44.82% |
| 2020 | -553.74 Thousand USD | 63.48% |
| 2019 | -1.51 Million USD | 61.17% |
| 2018 | -3.9 Million USD | -178.3% |
| 2017 | -1.4 Million USD | -748.49% |
| 2016 | -165.37 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -86.37 Thousand USD | 39.92% |
| 2024 Q2 | -79.25 Thousand USD | 8.24% |
| 2023 FY | -643.67 Thousand USD | -2.23% |
| 2023 Q3 | -439.55 Thousand USD | -1777.0% |
| 2023 Q1 | -36.94 Thousand USD | 92.79% |
| 2023 Q2 | -23.41 Thousand USD | 36.61% |
| 2023 Q4 | -143.76 Thousand USD | 67.29% |
| 2022 Q2 | -31.06 Thousand USD | 86.47% |
| 2022 Q4 | -512.55 Thousand USD | -2183.01% |
| 2022 FY | -629.62 Thousand USD | 21.49% |
| 2022 Q1 | -229.51 Thousand USD | 66.76% |
| 2022 Q3 | -22.45 Thousand USD | 27.73% |
| 2021 Q1 | -38.36 Thousand USD | 85.12% |
| 2021 FY | -801.95 Thousand USD | -44.82% |
| 2021 Q4 | -690.48 Thousand USD | -2178.3% |
| 2021 Q2 | -42.79 Thousand USD | -11.56% |
| 2021 Q3 | -30.3 Thousand USD | 29.19% |
| 2020 FY | -553.74 Thousand USD | 63.48% |
| 2020 Q1 | -218.93 Thousand USD | 63.14% |
| 2020 Q2 | -13.58 Thousand USD | 93.79% |
| 2020 Q3 | -63.42 Thousand USD | -366.76% |
| 2020 Q4 | -257.78 Thousand USD | -306.42% |
| 2019 Q3 | -459.74 Thousand USD | -130.84% |
| 2019 Q2 | -199.15 Thousand USD | 24.42% |
| 2019 Q1 | -263.51 Thousand USD | 88.02% |
| 2019 FY | -1.51 Million USD | 61.17% |
| 2019 Q4 | -594.01 Thousand USD | -29.21% |
| 2018 Q3 | -534.31 Thousand USD | 21.8% |
| 2018 FY | -3.9 Million USD | -178.3% |
| 2018 Q2 | -683.25 Thousand USD | -39.83% |
| 2018 Q1 | -488.62 Thousand USD | 63.38% |
| 2018 Q4 | -2.19 Million USD | -311.51% |
| 2017 Q2 | -19.36 Thousand USD | -1691.77% |
| 2017 Q1 | -1081.00 USD | 99.32% |
| 2017 FY | -1.4 Million USD | -748.49% |
| 2017 Q4 | -1.33 Million USD | -2667.53% |
| 2017 Q3 | -48.21 Thousand USD | -148.95% |
| 2016 Q3 | -5480.00 USD | 0.0% |
| 2016 Q4 | -159.89 Thousand USD | -2817.7% |
| 2016 FY | -165.37 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | -356.81% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 6.299% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -275.301% |
| CytoDyn Inc. | -18.05 Million USD | 96.436% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 98.909% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | -88952.033% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 64.561% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 87.24% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -2049.028% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -254.672% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | 93.368% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 98.84% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.151% |
| Resverlogix Corp. | -12.74 Million USD | 94.951% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -65.228% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 106.607% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 73.784% |
| Mesoblast Limited | -84.14 Million USD | 99.235% |
| GB Sciences, Inc. | -1.42 Million USD | 54.687% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 6.299% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 96.393% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 81.096% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 90.318% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 79.684% |
| ContraFect Corporation | -56.88 Million USD | 98.869% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 76.601% |
| BioStem Technologies, Inc. | -7.77 Million USD | 91.725% |
| LadRx Corporation | -3.82 Million USD | 83.166% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 95.944% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 42.477% |
| CSL Limited | 3.7 Billion USD | 100.017% |
| Biomind Labs Inc. | -1 Million USD | 36.245% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 30.89% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.786% |
| Nascent Biotech, Inc. | -2.22 Million USD | 71.134% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.103% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 113.097% |
| GeneThera, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 118.183% |
| Adynxx, Inc. | - USD | Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 58.095% |
| Marizyme, Inc. | -34.08 Million USD | 98.112% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 92.291% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -13.981% |
| Zenith Capital Corp. | -8.94 Million USD | 92.802% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 77.419% |
| Halberd Corporation | -75.05 Thousand USD | -757.664% |
| Genus plc | 6.4 Million USD | 110.057% |
| Pharming Group N.V. | -4.87 Million USD | 86.809% |
| MetaStat, Inc. | - USD | Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 67.597% |
| IMV Inc. | -38.67 Million USD | 98.336% |
| Affymax, Inc. | -15.04 Million USD | 95.722% |
| SYBLEU INC | -149.18 Thousand USD | -331.477% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 38.345% |
| Enzolytics Inc. | -2.14 Million USD | 70.045% |
| argenx SE | -425.04 Million USD | 99.849% |
| AVAX Technologies, Inc. | 6.69 Million USD | 109.617% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 54.088% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 51.8% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 82.819% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -2457.318% |
| Cell Source, Inc. | -4.32 Million USD | 85.118% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -33.249% |
| Q BioMed Inc. | -3.44 Million USD | 81.319% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 84.813% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 48.752% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 75.503% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 85.868% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 98.829% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 77.814% |
| Rebus Holdings, Inc. | -664 Thousand USD | 3.061% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 34.589% |
| Skye Bioscience, Inc. | -13.67 Million USD | 95.292% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 65.475% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 67.893% |
| ONE Bio Corp. | 13.68 Million USD | 104.705% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 66.694% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 42.779% |
| Agentix Corp. | -1.37 Million USD | 53.076% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 77.952% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 59.244% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -3594.834% |
| Kadimastem Ltd | -3.04 Million USD | 78.828% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -145.935% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -54.924% |
| NovAccess Global Inc. | -2.46 Million USD | 73.906% |
| Itoco Inc. | -919.14 Thousand USD | 29.97% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -192.477% |
| Mobile Lads Corp. | -554.55 Thousand USD | -16.072% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.845% |
| International Stem Cell Corporation | -663 Thousand USD | 2.914% |
| Bioxytran, Inc. | -3.82 Million USD | 83.15% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1122.791% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -3064.587% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 98.225% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 60.218% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 12.524% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 79.31% |
| Neutra Corp. | -229.48 Thousand USD | -180.486% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 96.33% |
| PureTech Health plc | -146.19 Million USD | 99.56% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 97.005% |
| IXICO plc | -1.43 Million USD | 55.207% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 93.218% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.472% |
| CSL Limited | 3.81 Billion USD | 100.017% |
| Cellectis S.A. | -108.85 Million USD | 99.409% |